BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 31599340)

  • 1. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
    Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
    Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
    Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
    Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
    J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
    Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
    Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
    Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
    Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
    Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Li X; Qi H; Qing G; Song Z; Xie L; Cao F; Chen X; Fan W
    Thorac Cancer; 2018 Aug; 9(8):1012-1017. PubMed ID: 29924498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
    Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced non small cell lung cancer: response to microwave ablation and EGFR Status.
    Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y
    Eur Radiol; 2017 Apr; 27(4):1685-1694. PubMed ID: 27436020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
    Elamin YY; Gomez DR; Antonoff MB; Robichaux JP; Tran H; Shorter MK; Bohac JM; Negrao MV; Le X; Rinsurogkawong W; Lewis J; Lacerda L; Roarty EB; Swisher SG; Roth JA; Zhang J; Papadimitrakopoulou V; Heymach JV
    Clin Lung Cancer; 2019 Jan; 20(1):43-47. PubMed ID: 30343004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
    Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
    Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
    PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
    Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
    Gomez DR; Tang C; Zhang J; Blumenschein GR; Hernandez M; Lee JJ; Ye R; Palma DA; Louie AV; Camidge DR; Doebele RC; Skoulidis F; Gaspar LE; Welsh JW; Gibbons DL; Karam JA; Kavanagh BD; Tsao AS; Sepesi B; Swisher SG; Heymach JV
    J Clin Oncol; 2019 Jun; 37(18):1558-1565. PubMed ID: 31067138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis.
    Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M; Zou Z
    J Cancer Res Clin Oncol; 2020 May; 146(5):1361-1367. PubMed ID: 32146563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.